132 related articles for article (PubMed ID: 19565364)
21. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
Twelves C
Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
[No Abstract] [Full Text] [Related]
22. Acute pain associated with oxaliplatin infusion: case report and literature review.
Clay TD; Ashley DA
J Oncol Pharm Pract; 2012 Dec; 18(4):421-4. PubMed ID: 22080592
[TBL] [Abstract][Full Text] [Related]
23. Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion.
Waddle M; Irvin M; Gupta E; Gibbs M; Kakar TS; Gannon NA; Arthurs JR; Fischer DL; Ailawadhi S
Chemotherapy; 2017; 62(5):295-300. PubMed ID: 28505615
[TBL] [Abstract][Full Text] [Related]
24. Disseminated intravascular coagulation and immune hemolytic anemia, possibly Evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review.
Meng L; Romano A; Smith E; Macik G; Grosh WW
Clin Colorectal Cancer; 2015 Mar; 14(1):e1-3. PubMed ID: 25600448
[No Abstract] [Full Text] [Related]
25. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
Oukkal M; Djilat K; Hadjam RM; Mahgoun M; Bentabak K; Graba A; Smail N; Kaci NA; Ahmed RB; Bouzid K
Bull Cancer; 2010 Apr; 97(4):469-74. PubMed ID: 20385517
[TBL] [Abstract][Full Text] [Related]
27. Common side effects and interactions of colorectal cancer therapeutic agents.
Holt K
J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
[No Abstract] [Full Text] [Related]
28. [Up to date chemotherapy for colon cancer].
Kubota T; Wada N; Kitajima M
Nihon Shokakibyo Gakkai Zasshi; 2007 Feb; 104(2):177-85. PubMed ID: 17283411
[No Abstract] [Full Text] [Related]
29. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T
J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155
[TBL] [Abstract][Full Text] [Related]
31. Recurrent priapism related to oxaliplatin infusion.
Adenis A; Mailliez A; Rigot JM; Gamelin L; Vanhuyse M; Gamelin E
J Clin Oncol; 2008 Feb; 26(6):1016-7. PubMed ID: 18281680
[No Abstract] [Full Text] [Related]
32. [Effective chemotherapy with bevacizumab/FOLFOX4 for neuroendocrine carcinoma of the ascending colon - a case study].
Tanabe H; Takase T; Morimoto D; Tanaka Y; Shibata A; Yaguchi T
Gan To Kagaku Ryoho; 2014 May; 41(5):661-4. PubMed ID: 24917018
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
André T; Boni C; Mounedji-Boudiaf L; Navarro M; Tabernero J; Hickish T; Topham C; Zaninelli M; Clingan P; Bridgewater J; Tabah-Fisch I; de Gramont A;
N Engl J Med; 2004 Jun; 350(23):2343-51. PubMed ID: 15175436
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Comella P; De Vita F; De Lucia L; Casaretti R; Avallone A; Orditura M; Rivellini F; Palmeri S; Catalano G; Comella G
Ann Oncol; 2000 Apr; 11(4):461-8. PubMed ID: 10847467
[TBL] [Abstract][Full Text] [Related]
36. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
37. [Standard chemotherapy for colonic neoplasms].
Hyodo I
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
[No Abstract] [Full Text] [Related]
38. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of carcinoma of the colorectum. The contribution of oxaliplatin].
Ravaioli A; Tassinari D; Panzini I
Tumori; 2000; 86(3 Suppl):S37-41. PubMed ID: 10969616
[No Abstract] [Full Text] [Related]
40. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Tsimberidou AM; Fu S; Ng C; Lim JA; Wen S; Hong D; Wheler J; Bedikian AY; Eng C; Wallace M; Camacho LH; Kurzrock R
Cancer; 2010 Sep; 116(17):4086-94. PubMed ID: 20564148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
